Patients in cohort 4 (BRAF-altered LGG) were treated by the combination of BRAF/MEK inhibitors (dabrafenib and trametinib), and patients in cohort 5 (osteosarcoma) were treated with the MTKI regorafenib. This evidence concerns the gene MAP2K7 and osteosarcoma.